ES2632497T3 - Mutantes de la polimerasa de HBV - Google Patents
Mutantes de la polimerasa de HBV Download PDFInfo
- Publication number
- ES2632497T3 ES2632497T3 ES12733748.3T ES12733748T ES2632497T3 ES 2632497 T3 ES2632497 T3 ES 2632497T3 ES 12733748 T ES12733748 T ES 12733748T ES 2632497 T3 ES2632497 T3 ES 2632497T3
- Authority
- ES
- Spain
- Prior art keywords
- residue
- mutated
- promoter
- domain
- hbv polymerase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1241—Nucleotidyltransferases (2.7.7)
- C12N9/1276—RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/07—Nucleotidyltransferases (2.7.7)
- C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/26—Endoribonucleases producing 5'-phosphomonoesters (3.1.26)
- C12Y301/26004—Ribonuclease H (3.1.26.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Polipéptido mutante que comprende un dominio de polimerasa de HBV mutado con una eliminación interior que interrumpe funcionalmente la actividad de la polimerasa, en el que dicha eliminación interior es de a lo sumo 30 residuos de aminoácidos, comprendiendo dicho dominio de polimerasa mutado la secuencia de aminoácidos representada en SEC ID nº: 1, pero que carece de por lo menos el residuo Tyr en la posición 203, el residuo Met en la posición 204, el residuo Asp en la posición 205, el residuo Asp en la posición 206, el residuo Val en la posición 207, el residuo Val en la posición 208 y el residuo Leu en la posición 209, en el que dicho polipéptido mutante comprende además un dominio de RNasaH mutado que comprende una eliminación de por lo menos 8 aminoácidos y de a lo sumo 60 aminoácidos que incluye por lo menos la parte de la SEC ID nº: 3 que se extiende desde el residuo Glu (E) en la posición 39 al residuo Ala (A) en la posición 46.
Description
5
15
25
35
45
55
65
manera no limitativa la cepa de Copenhague (Goebel et al., 1990, Virol. 179: 247; Johnson et al., 1993, Virol.
196: 381), la cepa de Wyeth y particularmente la cepa modificada de Ankara (MVA) (Antoine et al., 1998, Virol.
244: 365). Las condiciones generales para construir los poxvirus recombinantes son bien conocidas en la técnica. La molécula de ácido nucleico de la presente invención se inserta preferentemente en el genoma poxvírico en un lugar no esencial. El gen de la timidina cinasa es particularmente apropiado para la inserción en los vectores vaccinia de Copenhague y la eliminación II o III para la inserción en el vector MVA. Preferentemente, la molécula de ácido nucleico de la invención se inserta en la eliminación III del vector MVA y se coloca bajo el control de vaccinia 7.5K o promotor pH5R.
Otros vectores víricos en el contexto de la invención son morbillivirus que se pueden obtener a partir de una familia de paramyxoviridae, con preferencia específica para el virus del sarampión. Diversas cepas atenuadas están disponibles en la técnica (Brandler et al, 2008, CIMID, 31 : 271; Singh et al, 1999, J. virol. 73(6): 4823), tal como y sin limitación, las cepas Edmonston A y B (Griffin et al., 2001, Field's in Virology, 1401-1441), la cepa de Schwartz (Schwarz A, 1962, Am J Dis Child, 103: 216), la cepa S-191 o C-47 (Zhang et al, 2009, J Med Virol. 81 (8): 1477). La inserción entre los genes P y M es particularmente apropiada.
De acuerdo con la presente invención, la molécula(s) de ácido nucleico comprendida en el vector de la invención está en una forma adecuada para la expresión en una célula u organismo hospedador, lo que significa que la molécula de ácido nucleico es colocada bajo el control de las secuencias reguladoras apropiadas. Como se usa en la presente memoria, el término "elementos reguladores" se refiere a cualquier elemento que permite, contribuye o modula la expresión de una molécula de ácido nucleico en una célula o organismo hospedador determinado, incluyendo la replicación, duplicación, transcripción, empalme, traducción, estabilidad y/o transporte del ácido nucleico o su derivado (es decir, ARNm).
Es apreciado por los expertos en la materia que la elección de las secuencias reguladoras puede depender de tales factores como el propio vector, la célula hospedadora, el nivel de expresión deseado, etc. El promotor es de especial importancia. En el contexto de la invención, puede ser constitutivo que dirige la expresión de la molécula de ácido nucleico en muchos tipos de células hospedadoras o específica para ciertas células hospedadoras (por ejemplo, secuencias reguladoras específicas del hígado) o reguladas en respuesta a eventos específicos o factores exógenos (por ejemplo, por la temperatura, el aditivo nutriente, la hormona, etc.) o de acuerdo con la fase de un ciclo vírico (por ejemplo, temprano o tardío). También se pueden usar promotores que son reprimidos durante la etapa de producción en respuesta a eventos específicos o factores exógenos, con el fin de optimizar la producción del vector y eludir la toxicidad potencial del polipéptido(s) expresado.
Los promotores adecuados para la expresión constitutiva en células de mamíferos incluyen, de manera no limitativa citomegalovirus (CMV), el promotor temprano inmediato (Boshart et al, 1985, Cell 41: 521), el promotor RSV, el promotor tardío principal de adenovirus, el promotor de la fosfoglicerato cinasa (PGK) (Adra et al., 1987, Gene 60:65), el promotor de la timidina cinasa (TK) del virus del herpes simple (HSV)-1 y el promotor de la polimerasa de T7. Los promotores de virus vaccinia son particularmente adaptados para la expresión en los vectores poxvirus. El ejemplo representativo incluye de manera no limitativa, vaccinia 7.5 K, H5R, 11K7.5 (Erbs et al., 2008, Cancer Gene Ther. 15:18), TK, p28, p11 y el promotor K1L, así como promotores sintéticos, tales como los descritos en Chakrabarti et al. (1997, Biotechniques 23: 1094), Hammond et al. (1997, J. Virological Methods 66: 135) y Kumar y Boyle (1990, Virology 179: 151), así como promotores quiméricos tempranos/tardíos. Los promotores adecuados para la expresión sarampión mediado incluyen de manera no limitativa cualquier promotor que dirige la expresión de las unidades de transcripción del sarampión (Brandler y Tangy, 2008, CIMID 31: 271). Los promotores específicos del hígado incluyen de manera no limitativa los de la HMG-CoA reductasa (Luskey, 1987, Mol Cell Biol. 7: 1881); el elemento regulador de esterol 1 (SRE-1; Smith et al, 1990, J. Biol. Chem. 265: 2306); albúmina (Pinkert et al, 1987, Genes Dev. 1: 268); fosfoenolpiruvato carboxiquinasa (PEPCK) (Eisenberger y otros, 1992, Mol. Cell Biol. 12: 1396); alfa-1 antitripsina (Ciliberto et al., 1985, Cell 41: 531); transferrina humana (Mendelzon et al, 1990, Nucleic Acids Res. 18: 5717); y genes FIX (patente US nº 5.814.716).
Los expertos en la materia apreciarán que los elementos reguladores que controlan la expresión de la molécula de ácido nucleico de la invención pueden comprender además elementos adicionales para la iniciación, la regulación y/o terminación de la transcripción apropiada (por ejemplo, las secuencias de terminación de la transcripción polyA), el transporte de ARNm (por ejemplo, las secuencias de señal de localización nuclear), el procesamiento (por ejemplo, las señales de empalme), y la estabilidad (por ejemplo, los intrones y lass secuencias 5' y 3' no codificantes), la traducción (por ejemplo, un iniciador Met, secuencias líder tripartitas, sitios de unión de ribosoma IRES, secuencias de Shine-Dalgarno, etc) en la célula u organismo hospedador y etapas de purificación (por ejemplo, una etiqueta).
Las formas de realización particularmente preferidas de la invención están dirigidas a vectores (o partículas víricas) seleccionadas de entre el grupo que consiste en:
-Un vector de Ad defectuoso que comprende insertado en lugar de la región E1 una molécula de ácido nucleico colocada bajo el control de un promotor tal como el promotor CMV, y que codifica un polipéptido
17
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11305909 | 2011-07-12 | ||
EP11305909 | 2011-07-12 | ||
EP12305450 | 2012-04-18 | ||
EP12305450 | 2012-04-18 | ||
PCT/EP2012/063640 WO2013007772A1 (en) | 2011-07-12 | 2012-07-12 | Hbv polymerase mutants |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2632497T3 true ES2632497T3 (es) | 2017-09-13 |
Family
ID=46506427
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES12733748.3T Active ES2632497T3 (es) | 2011-07-12 | 2012-07-12 | Mutantes de la polimerasa de HBV |
Country Status (17)
Country | Link |
---|---|
US (3) | US9512412B2 (es) |
EP (1) | EP2732034B1 (es) |
JP (1) | JP6189293B2 (es) |
KR (1) | KR102061357B1 (es) |
CN (1) | CN103998604B (es) |
AU (1) | AU2012282506C1 (es) |
BR (1) | BR112014000627B1 (es) |
CA (1) | CA2841890C (es) |
DK (1) | DK2732034T3 (es) |
ES (1) | ES2632497T3 (es) |
HU (1) | HUE033789T2 (es) |
IL (1) | IL230402B (es) |
MX (1) | MX346835B (es) |
PE (2) | PE20141210A1 (es) |
RU (1) | RU2625021C2 (es) |
TW (2) | TWI623618B (es) |
WO (1) | WO2013007772A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI623618B (zh) * | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Hbv聚合酶突變體 |
TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
JP2015128397A (ja) * | 2014-01-08 | 2015-07-16 | 国立大学法人広島大学 | 亜リン酸デヒドロゲナーゼ遺伝子、および、当該遺伝子を用いた出芽酵母の選択的培養方法 |
WO2016020538A1 (en) * | 2014-08-08 | 2016-02-11 | Transgene Sa | Hbv vaccine and antibody combination therapy to treat hbv infections |
WO2016131945A1 (en) | 2015-02-20 | 2016-08-25 | Transgene Sa | Combination product with autophagy modulator |
WO2016167369A1 (ja) * | 2015-04-16 | 2016-10-20 | 国立研究開発法人産業技術総合研究所 | B型肝炎ウイルス分泌阻害剤 |
CA2991639A1 (en) | 2015-08-07 | 2017-02-16 | Arrowhead Pharmaceuticals, Inc. | Rnai therapy for hepatitis b virus infection |
CA3020426A1 (en) | 2016-04-13 | 2017-10-19 | Synthetic Genomics, Inc. | Recombinant arterivirus replicon systems and uses thereof |
CA3023022A1 (en) | 2016-05-04 | 2017-11-09 | Transgene Sa | Combination therapy with cpg tlr9 ligand |
JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
US20190328869A1 (en) | 2016-10-10 | 2019-10-31 | Transgene Sa | Immunotherapeutic product and mdsc modulator combination therapy |
EP3526332B1 (en) | 2016-10-17 | 2024-06-26 | Janssen Pharmaceuticals, Inc. | Recombinant virus replicon systems and uses thereof |
WO2018102678A1 (en) * | 2016-12-02 | 2018-06-07 | Taiga Biotechnologies, Inc. | Nanoparticle formulations |
EP3548625B1 (en) | 2016-12-05 | 2024-06-26 | Janssen Pharmaceuticals, Inc. | Compositions and methods for enhancing gene expression |
GB201705765D0 (en) * | 2017-04-10 | 2017-05-24 | Univ Oxford Innovation Ltd | HBV vaccine |
AU2018269319A1 (en) | 2017-05-15 | 2019-11-07 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
EP3624845A1 (en) | 2017-05-15 | 2020-03-25 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
US11389531B2 (en) | 2017-12-19 | 2022-07-19 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines |
EA202091513A1 (ru) | 2017-12-19 | 2020-09-09 | Янссен Сайенсиз Айрлэнд Анлимитед Компани | Вакцины против вируса гепатита b (hbv) и их применение |
US11020476B2 (en) | 2017-12-19 | 2021-06-01 | Janssen Sciences Ireland Unlimited Company | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) |
BR112020011976A2 (pt) * | 2017-12-19 | 2020-11-24 | Janssen Sciences Ireland Unlimited Company | composição e kit imunogênicos contra o vírus da hepatite b, usos dos mesmos, e molécula de ácido nucleico de ocorrência não natural |
EP3727441A1 (en) * | 2017-12-19 | 2020-10-28 | Janssen Sciences Ireland Unlimited Company | Methods and apparatus for the delivery of hepatitis b virus (hbv) vaccines |
EP3740245A4 (en) | 2018-01-19 | 2022-01-05 | Janssen Pharmaceuticals, Inc. | INDUCTION AND ENHANCEMENT OF IMMUNE RESPONSES USING RECOMBINATION REPLICON SYSTEMS |
EP3762010A4 (en) | 2018-03-06 | 2022-04-06 | Precigen, Inc. | HEPATITIS B VACCINES AND USES THEREOF |
EP3762020A1 (en) | 2018-03-07 | 2021-01-13 | Transgene | Parapoxvirus vectors |
AU2020297008A1 (en) * | 2019-06-18 | 2022-02-17 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis B virus (HBV) vaccines and HBV-targeting RNAi |
CA3141238A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Hepatitis b virus (hbv) vaccines and uses thereof |
WO2020255011A1 (en) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combination of hepatitis b virus (hbv) vaccines and anti-pd-1 or anti-pd-l1 antibody |
CN114340664A (zh) * | 2019-06-18 | 2022-04-12 | 爱尔兰詹森科学公司 | 乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合 |
EP3986457A1 (en) * | 2019-06-20 | 2022-04-27 | Janssen Sciences Ireland Unlimited Company | Carbohydrate nanocarrier delivery of hepatitis b virus (hbv) vaccines |
WO2020255055A1 (en) * | 2019-06-20 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Self-replicating rna molecules for hepatitis b virus (hbv) vaccines and uses thereof |
KR20220074917A (ko) * | 2019-09-30 | 2022-06-03 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 백신 및 hbv를 치료하는 방법 |
CN111548395A (zh) * | 2020-05-25 | 2020-08-18 | 中国农业科学院兰州兽医研究所 | 一种口蹄疫病毒二价多表位重组病毒样颗粒及其应用 |
KR20220117627A (ko) * | 2021-02-17 | 2022-08-24 | 주식회사 녹십자 | 백신 조성물과의 병용을 위한 hbv 특이적 항체를 포함하는 b형 간염 치료용 조성물 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2650838A1 (fr) | 1989-08-09 | 1991-02-15 | Transgene Sa | Vecteurs d'expression du facteur ix dans une cellule eucaryote superieure, procede de preparation de facteur ix par des animaux transgeniques et facteur ix obtenu |
EP1018344A3 (en) | 1991-08-26 | 2000-09-20 | Epimmune, Inc. | HLA-restricted hepatitis B virus CTL epitopes |
WO1994019011A1 (en) | 1993-02-26 | 1994-09-01 | The Scripps Research Institute | Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
AU702367B2 (en) | 1993-08-02 | 1999-02-18 | Scripps Research Institute, The | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
IL112820A0 (en) | 1994-03-07 | 1995-05-26 | Merck & Co Inc | Coordinate in vivo gene expression |
US5837520A (en) | 1995-03-07 | 1998-11-17 | Canji, Inc. | Method of purification of viral vectors |
SI0833934T2 (sl) | 1995-06-15 | 2013-04-30 | Crucell Holland B.V. | Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji |
CZ438398A3 (cs) | 1996-07-01 | 1999-03-17 | Rhone-Poulenc Rorer S. A. | Způsob přípravy rekombinantních adenovirů |
AU732703B2 (en) | 1996-11-20 | 2001-04-26 | Crucell Holland B.V. | An improved method for the production and purification of adenoviral vectors |
DE69739961D1 (de) | 1996-12-13 | 2010-09-23 | Schering Corp | Methoden zur Virus-Reinigung |
EP0988053A1 (en) | 1997-06-11 | 2000-03-29 | Aquila Biopharmaceuticals, Inc. | Purified saponins as oral adjuvants |
FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
JP3864610B2 (ja) | 1998-05-21 | 2007-01-10 | 旭硝子株式会社 | 水分散型撥水撥油剤組成物およびその製造方法 |
US7462354B2 (en) * | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
KR20030074787A (ko) * | 2001-02-05 | 2003-09-19 | 스트레스젠 바이오테크놀러지스 코포레이션 | B형 간염 바이러스 치료 |
EP1409012B1 (en) | 2001-06-22 | 2009-02-11 | The Wistar Institute Of Anatomy And Biology | Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
MXPA04004876A (es) | 2001-11-21 | 2004-07-30 | Univ Pennsylvania | Secuencias de acido nucleico y de aminoacido de adenovirus de simio, vectores que contienen los mismos y metodos de uso. |
FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
GB0328753D0 (en) | 2003-12-11 | 2004-01-14 | Royal Veterinary College The | Hepatitis B vaccines |
ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
CN100339488C (zh) * | 2004-12-07 | 2007-09-26 | 中山大学达安基因股份有限公司 | 乙型肝炎病毒基因组耐药突变检测方法 |
CN1313483C (zh) * | 2005-12-12 | 2007-05-02 | 浙江大学 | 鸭乙型肝炎病毒多聚酶蛋白ymdd功能区的抑制肽及应用 |
CN101472610A (zh) | 2006-06-20 | 2009-07-01 | 特朗斯吉有限公司 | 重组病毒疫苗 |
WO2008020656A1 (en) | 2006-08-14 | 2008-02-21 | Postech Foundation | A dna vaccine for curing chronic hepatitis b and a method of preparing same |
KR20080086687A (ko) | 2007-03-23 | 2008-09-26 | 주식회사 파나진 | 라미부딘 내성 b형 간염바이러스 검출을 위한 ρνα프로브, 키트 및 방법 |
US8415462B2 (en) | 2007-05-15 | 2013-04-09 | Transgene S.A. | Signaling peptides |
CA2691868C (en) | 2007-07-03 | 2016-12-20 | Transgene S.A. | Immortalized avian cell lines |
US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
DK2220242T3 (en) | 2007-11-28 | 2017-03-27 | Univ Pennsylvania | ABE-ADENOVIRA OF GROUP B, SADV-28,27, -29, -32, -33 AND -35 AND APPLICATIONS THEREOF |
CN101883858B (zh) | 2007-11-28 | 2015-07-22 | 宾夕法尼亚大学托管会 | 猿猴亚家族E腺病毒SAdV-39、-25.2、-26、-30、-37和-38及其应用 |
EP2220217A2 (en) | 2007-11-28 | 2010-08-25 | The Trustees of the University of Pennsylvania | Simian subfamily c adenoviruses sadv-40, -31, and-34 and uses thereof |
JP5661476B2 (ja) | 2008-03-04 | 2015-01-28 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | サルアデノウイルスSAdV−36、−42.1、−42.2および−44ならびにそれらの用途 |
AU2010209938A1 (en) | 2009-02-02 | 2011-08-25 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
CN102740881A (zh) | 2009-05-12 | 2012-10-17 | 特兰斯吉恩股份有限公司 | 正痘病毒产生和纯化方法 |
WO2011001565A1 (ja) | 2009-07-01 | 2011-01-06 | シャープ株式会社 | 液晶表示素子及び液晶表示装置 |
CA2770075C (en) * | 2009-08-07 | 2021-08-24 | Perrine Martin | Composition for treating hbv infection |
TWI623618B (zh) * | 2011-07-12 | 2018-05-11 | 傳斯堅公司 | Hbv聚合酶突變體 |
-
2012
- 2012-07-11 TW TW105141433A patent/TWI623618B/zh active
- 2012-07-11 TW TW101124905A patent/TWI575070B/zh active
- 2012-07-12 HU HUE12733748A patent/HUE033789T2/en unknown
- 2012-07-12 KR KR1020147003482A patent/KR102061357B1/ko active IP Right Grant
- 2012-07-12 WO PCT/EP2012/063640 patent/WO2013007772A1/en active Application Filing
- 2012-07-12 US US14/232,082 patent/US9512412B2/en active Active
- 2012-07-12 PE PE2014000055A patent/PE20141210A1/es active IP Right Grant
- 2012-07-12 DK DK12733748.3T patent/DK2732034T3/en active
- 2012-07-12 PE PE2019000402A patent/PE20190660A1/es unknown
- 2012-07-12 CA CA2841890A patent/CA2841890C/en active Active
- 2012-07-12 JP JP2014519553A patent/JP6189293B2/ja not_active Expired - Fee Related
- 2012-07-12 AU AU2012282506A patent/AU2012282506C1/en not_active Ceased
- 2012-07-12 EP EP12733748.3A patent/EP2732034B1/en active Active
- 2012-07-12 ES ES12733748.3T patent/ES2632497T3/es active Active
- 2012-07-12 MX MX2014000488A patent/MX346835B/es active IP Right Grant
- 2012-07-12 CN CN201280044383.1A patent/CN103998604B/zh active Active
- 2012-07-12 BR BR112014000627-0A patent/BR112014000627B1/pt not_active IP Right Cessation
- 2012-07-12 RU RU2014104360A patent/RU2625021C2/ru active
-
2014
- 2014-01-12 IL IL230402A patent/IL230402B/en active IP Right Grant
-
2016
- 2016-12-05 US US15/369,118 patent/US10190105B2/en active Active
-
2019
- 2019-01-25 US US16/257,784 patent/US10662414B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2632497T3 (es) | Mutantes de la polimerasa de HBV | |
Moss | Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. | |
US20070258997A1 (en) | Rescue of mumps virus from CDNA | |
AU675216B2 (en) | Recombinant swinepox virus | |
Spehner et al. | Construction of fowlpox virus vectors with intergenic insertions: expression of the beta-galactosidase gene and the measles virus fusion gene | |
EP3375874B1 (en) | Improved paramyxovirus vector | |
AU2001271423A1 (en) | Rescue of canine distemper virus from cDNA | |
EP1995310B1 (en) | Novel methods for rescue of RNA viruses | |
Machitani et al. | Development of an adenovirus vector lacking the expression of virus-associated RNAs | |
Wyatt et al. | Novel nonreplicating vaccinia virus vector enhances expression of heterologous genes and suppresses synthesis of endogenous viral proteins | |
US6673572B2 (en) | Methods for rescue of RNA viruses | |
Zwilling et al. | Functional F11L and K1L genes in modified vaccinia virus Ankara restore virus-induced cell motility but not growth in human and murine cells | |
Condit et al. | Orthopoxvirus genetics | |
Scheiflinger et al. | Evaluation of the thymidine kinase (tk) locus as an insertion site in the highly attenuated vaccinia MVA strain | |
AR084439A1 (es) | Plasmidos y vacunas recombinantes del virus sincicial respiratorio | |
EP2984167B1 (en) | Mutant vaccinia virus strains, uses thereof and method of producing the same | |
Parks et al. | Expression of a foreign gene by recombinant canine distemper virus recovered from cloned DNAs | |
Peeters et al. | A single-plasmid reverse genetics system for the rescue of non-segmented negative-strand RNA viruses from cloned full-length cDNA | |
WO2016157208A1 (en) | Recombinant mumps virus jeryl lynn 2 based vaccine | |
DK0752888T3 (da) | Nukleotid- og aminosyresekvenser af gB, gC- og gD-hunde-herpesvirus og anvendelser deraf | |
Hebben et al. | High level protein expression in mammalian cells using a safe viral vector: modified vaccinia virus Ankara | |
Alharbi et al. | Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity | |
Nishie et al. | Measles virus C protein facilitates transcription by the control of N protein-viral genomic RNA interaction in early phases of infection | |
Smith | Vaccinia virus vectors for gene expression | |
Moss | Vaccinia and other poxvirus expression vectors |